Last reviewed: June 30, 2026
Last updated: June 30, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy is a prescription injection containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that signals fullness to the brain and slows stomach emptying. Clinical trials show that patients using semaglutide lost an average of 15% of their body weight over 68 weeks. PlexusDx makes compounded semaglutide injections accessible without insurance, starting at $149/month from licensed 503A pharmacies.
What Is Wegovy and How Does It Work as a Weight Loss Drug
Wegovy is an injectable medication developed by Novo Nordisk that contains semaglutide, a hormone that mimics GLP-1, which your body naturally produces to regulate blood sugar and appetite. When semaglutide binds to GLP-1 receptors in the brain, it triggers feelings of satisfaction, reduces cravings, and slows the rate at which food moves through your stomach. This multi-system effect helps people eat less and feel fuller longer without willpower-driven calorie restriction.
The medication was originally developed to treat type 2 diabetes but was repurposed as a weight loss treatment after researchers observed significant weight reduction in diabetic patients taking it. In the STEP clinical trials, adults with obesity who took semaglutide injections once weekly lost 15-18% of their baseline body weight over 68 weeks, compared to 2-3% in the placebo group. This evidence led to FDA approval of Wegovy specifically for chronic weight management in 2021.
Clinical Evidence: Does Wegovy Actually Help People Lose Weight
Large-scale randomized controlled trials demonstrate that semaglutide-based treatments produce measurable, sustained weight loss in people with obesity or overweight status plus weight-related conditions. The STEP 1 trial enrolled 1,961 adults with obesity and no diabetes; after 68 weeks, the semaglutide group averaged 14.9% weight loss compared to 2.4% in the placebo group. Participants also showed improvements in blood pressure, waist circumference, and physical function, suggesting benefits beyond weight reduction alone.
Response to semaglutide varies among individuals, and genetic factors influence how effectively your body processes GLP-1 signals. PlexusDx uses the Precision Peptide Genetic Test to identify variations in genes like GLP1R (rs6923761) and FTO (rs9939609) that may predict your treatment response, allowing your provider to personalize dosing and potentially combine therapies for better outcomes. This precision approach helps identify which patients may benefit most from semaglutide monotherapy versus combination GLP-1 protocols.
Wegovy vs. Compounded Semaglutide: Understanding Your Options
Wegovy is a brand-name injectable semaglutide manufactured by Novo Nordisk and dispensed through traditional pharmacies, typically requiring insurance coverage or significant out-of-pocket costs. Compounded semaglutide injections contain the same active pharmaceutical ingredient but are prepared by licensed 503A compounding pharmacies and often cost less, with PlexusDx offering treatments starting at $149/month regardless of dose level. Both formulations contain semaglutide that works through identical biological mechanisms; the main differences lie in manufacturing, sourcing, availability without insurance, and pricing transparency.
PlexusDx compounded semaglutide is created in licensed 503A pharmacies regulated by state pharmacy boards and the FDA, ensuring consistent quality and sterility standards. The service is available in all 50 states without requiring insurance enrollment, membership fees, or insurance pre-authorization, making it accessible to patients who lack coverage or prefer transparent, predictable monthly costs. Your dose may need to increase over time as your body responds to treatment, but PlexusDx pricing remains flat at $149/month across all dose levels.
Side Effects, Safety, and Who Should Not Use Semaglutide
Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation, particularly when starting or increasing doses; these typically decrease over time as your body adjusts. More serious but rare side effects include pancreatitis, gallbladder problems, and thyroid concerns, which is why medical screening and ongoing provider communication are essential before and during treatment. Semaglutide is not recommended for people with a personal or family history of medullary thyroid cancer, those pregnant or planning pregnancy, or individuals with severe kidney or liver disease.
PlexusDx requires an initial medical consultation to review your health history, current medications, and contraindications before starting any GLP-1 therapy. Your provider will monitor you throughout treatment and adjust your dose gradually—starting low and increasing every 4 weeks—to minimize side effects and optimize results. HSA and FSA accounts are eligible to pay for PlexusDx semaglutide injections, offering additional financial flexibility alongside the transparent $149/month base price.
Personalized Weight Loss: Why Genetic Testing Matters for GLP-1 Success
Not every person responds equally to semaglutide because genetic variations in GLP-1 receptor structure, appetite-regulation pathways, and metabolic genes influence how your body processes and responds to this medication. The Precision Peptide Genetic Test screens for 150+ genetic insights across 14 peptide-signaling pathways, identifying key variants in GLP1R, GIPR, FTO, and MC4R genes that may predict your weight loss trajectory and optimal compound selection. This data-driven approach helps PlexusDx providers recommend whether you may benefit most from semaglutide alone, tirzepatide, combination therapy, or microdose protocols tailored to your biology.
Adding genetic insights to your treatment plan removes guesswork and accelerates the path to effective weight management by matching you with the therapy your body is most likely to respond to. PlexusDx offers the Precision Peptide Genetic Test as a $99 add-on after your first month of treatment, allowing you to start therapy promptly while collecting the genetic data that will refine your long-term plan. Patients who understand their genetic predispositions often achieve faster results, experience fewer side effects, and maintain better adherence to their prescribed protocols.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is Wegovy the same as semaglutide?
Wegovy is a brand-name version of semaglutide manufactured by Novo Nordisk. Compounded semaglutide contains the identical active ingredient but is prepared by licensed 503A pharmacies, often at lower cost. Both work through the same biological mechanism to reduce appetite and support weight loss.
How much weight can I expect to lose with Wegovy or semaglutide?
Clinical trials show average weight loss of 15-18% of baseline body weight over 68 weeks with semaglutide. Individual results vary based on genetics, lifestyle, and adherence. PlexusDx genetic testing helps predict your likely response and may identify whether combination therapy would benefit you more than semaglutide alone.
How much does PlexusDx semaglutide cost compared to Wegovy?
PlexusDx compounded semaglutide injections start at $149/month flat, with no insurance required and no flat per-compound pricing increases. Wegovy typically costs $300-400/month with insurance or significantly more without coverage. PlexusDx also accepts HSA and FSA payments, adding further savings flexibility.
Is compounded semaglutide as safe as Wegovy?
Compounded semaglutide from licensed 503A pharmacies meets strict regulatory and quality standards for sterility, potency, and safety. The active ingredient is identical to brand Wegovy, and safety profiles are comparable. PlexusDx requires medical consultation and ongoing provider monitoring to ensure safe use.
Can genetic testing help me know if semaglutide is right for me?
Yes. PlexusDx Precision Peptide Genetic Test identifies variations in GLP1R, GIPR, FTO, and MC4R genes that influence your weight loss response. This test costs $99 after your first month and helps your provider determine if semaglutide alone is optimal or if you'd benefit from tirzepatide, combination therapy, or alternative protocols.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding the Cost of Zepbound: What You Need to Know
Realistic Milestones: How Long for Wegovy to Start Working?